Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence
Dongfang Dai, Yifei Pei, Biqing Zhu, Deqiang Wang, Siyu Pei, Huan Huang, Qingchen Zhu, Xiuyu Deng, Jialin Ye, Jing Xu, Xiaoxiang Chen, Mingzhu Huang, Yichuan Xiao
Abstract
Tumor recurrence after chemoradiotherapy is challenging to overcome, and approaches to predict the recurrence remain elusive. Here, human cervical cancer tissues before and after concurrent chemoradiotherapy (CCRT) analyzed by single-cell RNA sequencing reveal that CCRT specifically promotes CD8 + T cell senescence, driven by atypical chemokine receptor 2 (ACKR2) + CCRT-resistant tumor cells. Mechanistically, ACKR2 expression is increased in response to CCRT and is also upregulated through the ligation of CC chemokines that are produced by activated myeloid and T cells. Subsequently, ACKR2 + tumor cells are induced to produce transforming growth factor β to drive CD8 + T cell senescence, thereby compromising antitumor immunity. Moreover, retrospective analysis reveals that ACKR2 expression and CD8 + T cell senescence are enhanced in patients with cervical cancer who experienced recurrence after CCRT, indicating poor prognosis. Overall, we identify a subpopulation of CCRT-resistant ACKR2 + tumor cells driving CD8 + T cell senescence and tumor recurrence and highlight the prognostic value of ACKR2 and CD8 + T cell senescence for chemoradiotherapy recurrence.